BBOT
BridgeBio Oncology Therapeutics Inc.
NASDAQHealthcareBiotechnologyUS
Rating:B-
Company Profile
CEO
Eli Wallace
IPO Date
2025-08-12
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
BridgeBio Oncology Therapeutics Inc.
CEO
Eli Wallace
IPO Date
2025-08-12
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 1,103,837 |
| $7.66 |
| 5 May 2026 | Ben Yong | Chief Med & Dev Officer | F-InKind | Disposed | 1,047 | $9.03 |
| 5 May 2026 | Beltran Pedro | director, officer: President and CEO | F-InKind | Disposed | 1,047 | $9.03 |
| 5 May 2026 | Mehra Uneek | other: Former Officer | F-InKind | Disposed | 524 | $9.03 |
| 30 Apr 2026 | Cobo Marc | Principal Accounting Officer | Disposed | 0 | $0.00 |
| 30 Apr 2026 | Cobo Marc | Principal Accounting Officer | Disposed | 129,090 | $9.59 |
| 30 Apr 2026 | Cobo Marc | Principal Accounting Officer | Disposed | 25,125 | $10.19 |
| 30 Apr 2026 | Elmelech Idan | COO & Principal Financial Ofcr | Disposed | 0 | $0.00 |
| 30 Apr 2026 | Elmelech Idan | COO & Principal Financial Ofcr | Disposed | 129,678 | $4.17 |